Literature DB >> 33431898

Plasma and follicular fluid osteopontin levels during ovarian cycle and their correlation with follicular fluid vascular endothelial growth factor levels.

Yoshimitsu Kuwabara1, Shuichi Ono2, Akira Katayama3, Sachiko Kurihara2,3, Yumiko Oishi3, Toshiyuki Takeshita2.   

Abstract

Osteopontin (OPN) is a multifunctional secreted glycoprotein. We evaluated OPN concentrations in blood and follicular fluid (FF) during the ovarian cycle and their relationship with the production of vascular endothelial growth factor (VEGF), which is involved in the pathophysiology of ovarian hyperstimulation syndrome (OHSS). Twenty-two women undergoing in vitro fertilization (minimal stimulation protocol with clomiphene citrate) were enrolled. Samples were collected (a) on the third day of withdrawal bleeding, (b) 2 days before oocyte retrieval, and (c) on the day of oocyte retrieval. FF was collected during oocyte retrieval. The OPN concentration in each specimen and the VEGF concentration in FF was measured by enzyme-linked immunosorbent assays. Plasma OPN concentrations were (in ng/mL): (a) 416 ± 37.2, (b) 378 ± 35.8, and (c) 390 ± 40.0, with no significant differences between the groups. The OPN concentration in FF was 106 ± 13.4 ng/mL. A positive correlation was found between OPN concentrations in FF and plasma samples. A positive correlation was also found between plasma OPN and FF VEGF concentrations, irrespective of the blood-sampling period. Plasma OPN concentration is suggested to reflect the FF VEGF level at oocyte retrieval and maybe a novel clinical marker for predicting the risk for OHSS.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33431898      PMCID: PMC7801375          DOI: 10.1038/s41598-020-79453-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  14 in total

1.  Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment.

Authors:  Zhifei Shao; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

2.  Gonadotropin regulation and role of ovarian osteopontin in the periovulatory period.

Authors:  Yoshimitsu Kuwabara; Akira Katayama; Ryoko Tomiyama; Hu Piao; Sachiko Kurihara; Shuichi Ono; Katsuya Mine; Shigeo Akira; Hideo Orimo; Toshiyuki Takeshita
Journal:  J Endocrinol       Date:  2014-10-28       Impact factor: 4.286

Review 3.  Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.

Authors:  Sérgio Reis Soares; Raúl Gómez; Carlos Simón; Juan Antonio García-Velasco; Antonio Pellicer
Journal:  Hum Reprod Update       Date:  2008-04-02       Impact factor: 15.610

4.  Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.

Authors:  Tzu-Hao Wang; Shang-Gwo Horng; Chia-Lin Chang; Hsien-Ming Wu; Yi-Ju Tsai; Hsin-Shih Wang; Yung-Kuei Soong
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

5.  Follicular-phase ovarian follicular fluid and plasma cytokine profiling of natural cycle in vitro fertilization patients.

Authors:  N Ellissa Baskind; Nicolas M Orsi; Vinay Sharma
Journal:  Fertil Steril       Date:  2014-05-27       Impact factor: 7.329

6.  The blood-follicle barrier (BFB) in disease and in ovarian function.

Authors:  Michelle K Y Siu; C Yan Cheng
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Isolation and characterization of two sialoproteins present only in bone calcified matrix.

Authors:  A Franzén; D Heinegård
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

Review 8.  The nature and significance of osteopontin.

Authors:  W T Butler
Journal:  Connect Tissue Res       Date:  1989       Impact factor: 3.417

Review 9.  The multiple functions and mechanisms of osteopontin.

Authors:  Mehmet Arif Icer; Makbule Gezmen-Karadag
Journal:  Clin Biochem       Date:  2018-07-10       Impact factor: 3.281

10.  Osteopontin expression in cardiovascular diseases.

Authors:  C M Giachelli; L Liaw; C E Murry; S M Schwartz; M Almeida
Journal:  Ann N Y Acad Sci       Date:  1995-04-21       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.